Casi Pharma rises on FDA nod to test blood disorder drug in humans

CASI Pharmaceuticals

15/05/2024 15:21

** Shares of drug developer CASI Pharmaceuticals  CASI.O 
rise ~7% to $3.38   
    ** Co says the U.S. Food and Drug Administration has cleared
application to test its experimental drug in adults with chronic
Immune Thrombocytopenia (ITP)
    ** ITP is a type of platelet disorder that keeps blood from
clotting, which can lead to bruising and bleeding 
     ** The drug candidate, CID-103, is a monoclonal antibody
that binds to a protein called CD38, which is found on some
types of blood cells and in high levels on some cancer cells
-CASI    
    ** Including session gains, stock down 53% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))